Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

- Asthma | Chronic Obstructive Pulmonary Disease (COPD)
- Completed

Study Title: Open-Label Assessment of the Albuterol Spiromaxֲ® Dry Powder Inhaler (DPI)

Teva Identifier: ABS-AS-308

ClinicalTrials.gov Identifier: NCT01857323

Study Status: Completed

Trial Condition(s): Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Albuterol Spiromaxֲ®

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Child, Adult, Older Adult

Age Range: 4 Years and older

Trial Duration: 05/01/2013 - 09/01/2013

Phase: Phase 3

Study Type

Interventional